Lack of effect of vitamin E therapy on the anemia of patients receiving hemodialysis

Abstract

We conducted a prospective, randomized, double-blind therapeutic trial of vitamin E as an erythropoietic agent in a group of patients with chronic renal failure who were undergoing chronic hemodialysis. Sixteen patients received 400 IU of vitamin E (d-α-tocopheryl acetate) by mouth twice daily and 19 patients received a placebo twice daily for 20 wk. The serum vitamin E concentration increased from 1.3 to 2.6 mg/dl in the treated group and decreased from 1.3 to 1.1 in the placebo group. For the treated group the initial hematocrit was 24.8 ± 3.0 (mean ± SD) and the final hematocrit was 25.8 ± 3.8. For the placebo group the initial hematocrit was 24.9 ± 3.0 and the final hematocrit was 23.5 ± 2.7. The treated group received a total of 40 blood transfusions, and the placebo group received a total of 35 blood transfusions. Thus, vitamin E had no effect on the anemia or transfusion requirements of patients undergoing chronic hemodialysis for chronic renal failure.